Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cidara Therapeutics Inc CDTX

Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak... see more

Recent & Breaking News (NDAQ:CDTX)

Cidara Therapeutics Announces $105 Million Private Placement

GlobeNewswire 3 days ago

Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference

GlobeNewswire 5 days ago

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

GlobeNewswire November 7, 2024

Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences

GlobeNewswire October 31, 2024

Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024

GlobeNewswire October 16, 2024

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire October 4, 2024

Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference

GlobeNewswire September 25, 2024

Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza

GlobeNewswire September 23, 2024

Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts

GlobeNewswire September 19, 2024

Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388

GlobeNewswire September 12, 2024

Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 5, 2024

Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer

GlobeNewswire August 19, 2024

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

GlobeNewswire August 13, 2024

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 3, 2024

Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference

GlobeNewswire May 30, 2024

Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire May 16, 2024

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

GlobeNewswire May 15, 2024

Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules

GlobeNewswire May 15, 2024

ROSEN, A LEADING NATIONAL FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

Newsfile May 15, 2024

Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire May 15, 2024